

Appendix 3F

Final share buy-back notice (*except* minimum holding buy-back)

Introduced 1/9/99. Origin: Appendices 7D and 7E. Amended 30/9/2001, 11/01/10

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
ACTINOGEN MEDICAL LIMITED	14 086 778 476

We (the entity) give ASX the following information.

Description of buy-back

1	Type of buy-back	Employee share scheme buy-back
---	------------------	--------------------------------

Details of all shares/units bought back

2	Number of shares/units bought back	3,000,000
3	Total consideration paid or payable for the shares/units	Nil, the consideration being the release of Dr Bill Ketelbey by the Company from the obligation to repay the share loan advance to Dr Ketelbey in relation to the shares cancelled.
4	If buy-back is an on-market buy-back - highest and lowest price paid	Not applicable

+ See chapter 19 for defined terms.


Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:


.....
(Company secretary)

Date: 31 January 2020

Print name: Peter Webse.

== == == == ==